Clarity Pharmaceuticals Ltd Cash Flow Conversion Efficiency
Clarity Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has a cash flow conversion efficiency ratio of -0.240x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-44.75 Million ≈ $-31.67 Million USD) by net assets (AU$186.11 Million ≈ $131.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Clarity Pharmaceuticals Ltd (2018–2026)
Cash flow conversion efficiency of Clarity Pharmaceuticals Ltd from 2018 to 2026. This chart illustrates how Clarity Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CU6 live share price for real-time trading data and today's change.
Clarity Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained
Clarity Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Clarity Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see CU6 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
THARISA NON LIST. DL-001
F:7YZ
|
N/A |
|
AirAsia X Bhd
KLSE:5238
|
-4.848x |
|
Yung Chi Paint & Varnish Mfg Co Ltd
TW:1726
|
-0.003x |
|
Chang Lan Electric Technology Co Ltd
SHE:002879
|
0.062x |
|
Entree Resources Ltd
TO:ETG
|
0.013x |
|
Gigasolar Materials
TWO:3691
|
-0.036x |
|
Shandong Synthesis Electronic Technology Co Ltd
SHE:300479
|
0.008x |
|
Dipula Income Fund Ltd
JSE:DIB
|
0.021x |
Annual Cash Flow Conversion Efficiency for Clarity Pharmaceuticals Ltd (2018–2026)
The table below shows the annual cash flow conversion efficiency of Clarity Pharmaceuticals Ltd from 2018 to 2026. Review CU6 free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$186.11 Million ≈ $131.68 Million |
AU$-92.55 Million ≈ $-65.48 Million |
-0.497x | +18.08% |
| 2025-06-30 | AU$90.23 Million ≈ $63.84 Million |
AU$-54.77 Million ≈ $-38.75 Million |
-0.607x | -105.38% |
| 2024-06-30 | AU$146.30 Million ≈ $103.51 Million |
AU$-43.24 Million ≈ $-30.59 Million |
-0.296x | +25.66% |
| 2023-06-30 | AU$69.18 Million ≈ $48.95 Million |
AU$-27.50 Million ≈ $-19.46 Million |
-0.398x | -175.41% |
| 2022-06-30 | AU$92.24 Million ≈ $65.26 Million |
AU$-13.31 Million ≈ $-9.42 Million |
-0.144x | +61.87% |
| 2021-06-30 | AU$20.28 Million ≈ $14.35 Million |
AU$-7.68 Million ≈ $-5.43 Million |
-0.379x | +54.78% |
| 2020-06-30 | AU$8.16 Million ≈ $5.77 Million |
AU$-6.83 Million ≈ $-4.83 Million |
-0.837x | -108.35% |
| 2019-06-30 | AU$9.23 Million ≈ $6.53 Million |
AU$-3.71 Million ≈ $-2.62 Million |
-0.402x | +48.30% |
| 2018-06-30 | AU$1.93 Million ≈ $1.37 Million |
AU$-1.50 Million ≈ $-1.06 Million |
-0.777x | -- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic rad… Read more